Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Hope on the Impact of Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

July 6th 2020

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Early Biomarker Data Provide Framework for Precision Medicine-Based Trials in Prostate Cancer

July 2nd 2020

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.

Dr. Shore on the Safety Profiles of Relugolix and Leuprolide in Prostate Cancer

July 1st 2020

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Pivotal Phase 3 CONTACT-02 Trial of Cabozantinib/Atezolizumab in mCRPC Initiated

June 30th 2020

Exelixis, Inc. has launched the phase 3 CONTACT-02 trial examining cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer who have received prior treatment with 1 novel hormonal therapy.

Dr. Rana on the Prevalence of Pathogenic Variants in Prostate Cancer

June 30th 2020

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Atezolizumab/Radium-223 Combo Shows No Benefit in mCRPC, But Biomarker Work Planned

June 29th 2020

Michael J. Morris, MD, discusses the combination of atezolizumab and radium-223 dichloride, which did not demonstrate a clinical benefit in patients with metastatic castration-resistant prostate cancer.

Systematic Germline Genetic Testing Is Feasible in Veterans With Metastatic Prostate Cancer

June 29th 2020

Alexandra Sokolova, MD, discusses the implementation of systematic germline genetic testing in veterans with metastatic prostate cancer appeared to be feasible due to high consent rates, especially with direct oncologist involvement.

Dr. Saad on Unanswered Questions From the SPARTAN Trial in M0CRPC

June 29th 2020

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Dr. Sokolova on the Rationale for Systematic Germline Testing in Prostate Cancer

June 29th 2020

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Dr. Agarwal on Cohort 6 Results ​From the COSMIC-021 Trial in mCRPC

June 29th 2020

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

NICE Passes on Abiraterone for Newly Diagnosed, High-Risk Metastatic Hormone-Sensitive Prostate Cancer

June 26th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend abiraterone acetate with prednisone/prednisolone plus androgen deprivation therapy as a treatment for patients with newly diagnosed, high-risk hormone-sensitive metastatic prostate cancer.

Dr. Chi on the Utility of Liquid Biopsy in Prostate Cancer

June 26th 2020

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPC

June 26th 2020

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Dr. Saad on Unique Characteristics of Apalutamide in M0CRPC

June 26th 2020

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

FDA Approval Insights: Olaparib in HRR-Mutant mCRPC

June 25th 2020

In our exclusive interview, Neeraj Agarwal, MD, discusses the recent FDA approval of olaparib in homologous recombination repair–mutant metastatic castration-resistant prostate cancer.

Dr. Sokolova on Challenges of Germline Testing in Metastatic Prostate Cancer

June 24th 2020

Alexandra Sokolova, MD, discusses the challenges of germline testing in patients with metastatic prostate cancer. 

Dr. Rana on Germline Genetic Testing in Advanced Prostate Cancer

June 23rd 2020

Huma Q. Rana, MD, MPH, discusses germline genetic testing in men with advanced prostate cancer.

Dr. Saad on the Safety Profile of Apalutamide in M0CRPC

June 23rd 2020

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer.

Dr. Sokolova on Implementing a Germline Testing Protocol for Metastatic Prostate Cancer

June 22nd 2020

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

FDA Grants Priority Review to Relugolix for Advanced Prostate Cancer

June 22nd 2020

The FDA has granted a priority review designation to a new drug application for relugolix as a treatment for patients with advanced prostate cancer.

NEXT PAGE
PREVIOUS PAGE